One example of this would be that CD123, which fell outside of the highest scoring targets after Cheever, has been used to target CLL in combination with CD3 via dual-affinity retargeting antibodies (DARTs) [72,73]. This evidence concerns the gene IL3RA and B-cell chronic lymphocytic leukemia.